EUR 106.78 For Business Accounts Only

Portola Pharmaceuticals Inc - Strategic SWOT Analysis Review

Portola Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company that discovers, and develops therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc Key Recent Developments

May 11,2020: Portola Pharmaceuticals reports first quarter 2020 financial results and provides corporate update
May 06,2020: Alexion to buy Portola Pharmaceuticals for $1.41bn
May 05,2020: Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
Apr 23,2020: Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020
Mar 18,2020: Portola Pharmaceuticals announces proactive steps supporting public health efforts to combat coronavirus (COVID-19)

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.